Illumina (NASDAQ:ILMN) Given New $310.00 Price Target at Royal Bank Of Canada

Illumina (NASDAQ:ILMN) had its price target increased by Royal Bank Of Canada from $230.00 to $310.00 in a report released on Monday morning,Benzinga reports. They currently have an outperform rating on the life sciences company’s stock.

A number of other research firms have also issued reports on ILMN. Argus increased their target price on Illumina from $180.00 to $235.00 and gave the company a “buy” rating in a report on Thursday, September 3rd. Deutsche Bank Aktiengesellschaft cut shares of Illumina to a “hold” rating in a report on Wednesday, August 5th. Stifel Nicolaus lifted their price target on Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a report on Friday, July 31st. Canaccord Genuity Group boosted their price target on Illumina from $190.00 to $205.00 and gave the company a “hold” rating in a research note on Monday, August 3rd. Finally, UBS Group upgraded shares of Illumina from a “neutral” rating to a “buy” rating and increased their price target for the stock from $135.00 to $260.00 in a research note on Wednesday, September 9th. Ten equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $219.69.

Illumina Stock Up 7.6%

ILMN stock opened at $293.69 on Monday. Illumina has a 12 month low of $88.00 and a 12 month high of $296.25. The firm has a 50 day simple moving average of $221.46 and a 200 day simple moving average of $177.17. The firm has a market cap of $44.35 billion, a PE ratio of 54.79, a P/E/G ratio of 3.87 and a beta of 1.41. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same period last year, the company posted $1.19 EPS. The company’s revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Equities research analysts forecast that Illumina will post 5.36 earnings per share for the current fiscal year.

Insider Buying and Selling at Illumina

In related news, Director Keith Meister sold 457,858 shares of the stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the completion of the sale, the director owned 2,372,694 shares in the company, valued at $474,776,069.40. This represents a 16.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last ninety days, insiders sold 2,061,850 shares of company stock worth $436,479,102. 2.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Illumina

Several large investors have recently bought and sold shares of the stock. Baker Tilly Wealth Management LLC raised its position in shares of Illumina by 3.3% during the third quarter. Baker Tilly Wealth Management LLC now owns 1,297 shares of the life sciences company’s stock valued at $355,000 after buying an additional 42 shares during the last quarter. Argent Capital Management LLC acquired a new position in Illumina in the 3rd quarter valued at approximately $4,005,000. QRG Capital Management Inc. lifted its position in shares of Illumina by 8.1% in the 2nd quarter. QRG Capital Management Inc. now owns 7,261 shares of the life sciences company’s stock worth $1,277,000 after acquiring an additional 546 shares during the period. Envestnet Portfolio Solutions Inc. lifted its position in Illumina by 18.6% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 6,935 shares of the life sciences company’s stock worth $1,219,000 after purchasing an additional 1,090 shares during the period. Finally, Tidal Investments LLC lifted its holdings in shares of Illumina by 10.3% during the 2nd quarter. Tidal Investments LLC now owns 93,728 shares of the life sciences company’s stock worth $16,480,000 after acquiring an additional 8,726 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina News Roundup

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Royal Bank of Canada raised its price target for Illumina from $230 to $310 and maintained an “outperform” rating. The revised target implies additional upside from the stock’s current level and helped support buying momentum. Royal Bank Of Canada Issues Positive Forecast for Illumina Stock Price
• Positive Sentiment: RBC also characterized Illumina’s clinical sequencing revenue as a durable mid-teens growth business, reinforcing expectations for sustained demand for sequencing instruments, consumables and related services. Illumina’s Clinical Sequencing Revenue Seen as Durable Mid-Teens Grower
• Positive Sentiment: Illumina reached a new one-year high following the analyst upgrade, indicating strong market momentum. The move follows recent increases to analyst targets, the company’s higher 2026 guidance, and its addition to the S&P 500, which can increase demand from index-tracking funds. Illumina Sets New One-Year High on Analyst Upgrade
• Neutral Sentiment: The rally appears driven primarily by follow-through from earlier catalysts rather than a new earnings release. Illumina’s latest reported quarter exceeded consensus estimates for revenue and adjusted earnings, while full-year 2026 guidance was raised.
• Negative Sentiment: Quiver Quantitative data shows substantial insider selling over the past six months, with no reported open-market purchases. This may signal profit-taking or create a valuation overhang, particularly after the stock’s sharp advance.

Illumina Company Profile

Illumina, Inc develops and manufactures technologies used to analyze genetic variation and biological function. Its products are primarily based on next-generation sequencing, a method that enables researchers and clinicians to read DNA and RNA for applications including genomic research, disease studies, drug development and clinical testing.

The company offers sequencing instruments, consumables such as reagent kits and flow cells, and related software and informatics solutions. Illumina also provides services and support designed to help customers prepare samples, run sequencing workflows, interpret genomic data and integrate results into research or clinical operations.

Founded in 1998 and headquartered in San Diego, California, Illumina serves customers worldwide, including academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, clinical laboratories and other healthcare organizations.